The effect of letrozole on liver function test in polycystic ovarian syndrome with subfertile patient with and without fatty liver disease

Binita Sarkar; Fatema Akter; Najmatun Jikria; Koushik Sikdar

doi:10.18203/2320-1770.ijrcog20250172

Authors

Binita Sarkar Department of Obstetrics and Gynecology, Shaheed Syed Nazrul Islam Medical College Hospital, Kishoreganj, Bangladesh
Fatema Akter Department of Obstetrics and Gynecology, Shaheed Syed Nazrul Islam Medical College Hospital, Kishoreganj, Bangladesh
Najmatun Jikria Medical Officer, 250 Beded Sadar Hospital, Naogaon, Bangladesh
Koushik Sikdar Department of Surgery, Shaheed Syed Nazrul Islam Medical College Hospital, Kishoreganj, Bangladesh

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20250172

Keywords:

Fatty liver disease, Letrozole, Liver function tests, Polycystic ovarian syndrome, Subfertility

Abstract

Background: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder characterized by subfertility, insulin resistance and metabolic dysfunction, commonly associated with nonalcoholic fatty liver disease (NAFLD). Letrozole is a first line ovulation induction agent, superior to clomiphene citrate but liver effects in PCOS patients with and without fatty liver disease has not been sufficiently explored. This study aims to determine the effect of letrozole on liver function tests (LFTs) in subfertile PCOS patients stratified by the presence of fatty liver disease.

Methods: This cross-sectional observational study carried out at department of obstetrics and gynecology, Shaheed Syed Nazrul Islam Medical College Hospital, Kishoreganj, Bangladesh from 1^st October 2023 to 31^st of March 2024. The study included 150 subfertile women with PCOS who had been divided equally between groups with or without fatty liver disease. The baseline characteristics, metabolic profiles and LFT parameters were analyzed.

Results: Across both groups, letrozole improved ovulation and pregnancy rates, but the patients with fatty liver disease had markedly increased LFT parameters compared to those without, for example (ALT: 39±7.9 versus 25.5±6.4 U/l; p<0.001). Fatty liver group also had worse metabolic markers. In patients with fatty liver, 20% of patients developed adverse liver effects.

Conclusions: Letrozole is effective for ovulation induction in subfertile PCOS patients but is hepatotoxic particularly if the patient has associated fatty liver disease. In high risk groups, therapists should closely monitor liver function.

Metrics

Metrics Loading ...

References

Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29(2):181-91. DOI: https://doi.org/10.1016/S0002-9378(15)30642-6

ESHRE TR, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. DOI: https://doi.org/10.1016/j.fertnstert.2003.10.004

Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067-73. DOI: https://doi.org/10.1093/humrep/des232

Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes. 2002;26(7):883-96. DOI: https://doi.org/10.1038/sj.ijo.0801994

Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014;20(26):8351. DOI: https://doi.org/10.3748/wjg.v20.i26.8351

Casper RF. Letrozole versus clomiphene citrate: which is better for ovulation induction? Fertil Steril. 2009;92(3):858-9. DOI: https://doi.org/10.1016/j.fertnstert.2007.03.094

Ohkawa K, Nakabori T, Mukai K, Kozumi K, Urabe M, Kai Y, et al. Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study. PloS One. 2024;19(10):e0311930. DOI: https://doi.org/10.1371/journal.pone.0311930

Skarra DV, Hernández-Carretero A, Rivera AJ, Anvar AR, Thackray VG. Hyperandrogenemia induced by letrozole treatment of pubertal female mice results in hyperinsulinemia prior to weight gain and insulin resistance. Endocrinology. 2017;158(9):2988-3003. DOI: https://doi.org/10.1210/en.2016-1898

Mikolašević I, Milić S, Orlić L, Stanić M, Štimac D, Mavrinac V, et al. Treatment of non-alcoholic fatty liver disease. Med Fluminens. 2016;52(2):157-64.

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51. DOI: https://doi.org/10.1093/humrep/dep399

Rocha AL, Faria LC, Guimarães TC, Moreira GV, Cândido AL, Couto CA, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Investig. 2017;40:1279-88. DOI: https://doi.org/10.1007/s40618-017-0708-9

Zhao Y, Wang H, He T, Ma B, Chen G, Tzeng C. Knockdown of Yap attenuates TAA-induced hepatic fibrosis by interaction with hedgehog signals. J Cell Commun Signal. 2023;17(4):1335-54. DOI: https://doi.org/10.1007/s12079-023-00775-6

Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212-8. DOI: https://doi.org/10.2337/dc06-2247

Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-92. DOI: https://doi.org/10.1210/jc.2013-2350